Carcinogenesis cannot be explained only by genetic alterations, but also involves
epigenetic processes. Modification of histones by acetylation plays a key role in epigenetic …

Simple Summary Although in the last decades the clinical outcome of cancer patients
considerably improved, the major drawbacks still associated with chemotherapy are the …

Background Breast cancer is the second leading cause of death among women after lung
cancer. Despite the improvement in prevention and in therapy, breast cancer still remains a …

Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, is a widely used anticonvulsant
drug that is currently undergoing clinical evaluation for anticancer therapy due to its anti …

Histone deacetylases (HDACs) can regulate cancer progression and its inhibitors (HDACIs)
have been widely used for cancer therapy. Valproic acid (VPA, 2-propylpentanoic acid) can …

Background: Despite effective treatments, metastatic colorectal cancer (mCRC) prognosis is
still poor, mostly in RAS-mutated tumors, thus suggesting the need for novel combinatorial …

Vascular endothelial growth inhibitor (VEGI; also referred to as TNFSF15 or TL1A) is
involved in the modulation of vascular homeostasis. VEGI is known to operate via two …

Introduction Affective disorders are a major global burden, with approximately 15% of
people worldwide suffering from some form of affective disorder. In patients experiencing …

Background Drugs with histone deacetylase inhibitory (HDACi) properties have shown to
decrease prostate cancer (PCa) cell growth in vitro. Methods A cohort of 9261 PCa cases …

Despite the concerning adverse effects on tumour development, epigenetic drugs are very
promising in cancer treatment. The aim of this study was to compare the differential effects of …